Older Weight-Loss Drug Mysimba Presents Potential Alternative to Newer Injectables

A previously available weight-loss medication, Mysimba, is gaining renewed attention as a potential alternative to newer, more popular injectable drugs like Mounjaro and Wegovy. Experts suggest that this oral medication, a combination of naltrexone and bupropion, may offer significant benefits, especially for individuals who struggle with cravings and binge eating.

While GLP-1 agonists such as Mounjaro and Wegovy have garnered considerable attention, partly due to celebrity endorsements, Mysimba offers a different approach. In clinical trials, patients using Mysimba experienced an average weight loss of approximately 8 percent of their starting weight. This result, while potentially lower than that achieved with some of the latest GLP-1 medications, is still considered clinically significant.

Mysimba works by targeting appetite and cravings in the brain. Naltrexone, one of its components, is known to affect the brain's reward pathways, potentially reducing the urge to overeat. Bupropion, an antidepressant, is also believed to play a role in appetite regulation. This dual action makes Mysimba particularly suited for individuals whose weight gain is linked to psychological factors such as emotional eating or specific food cravings.

GLP-1 drugs, in contrast, mimic a natural hormone released after eating, signaling fullness to the brain. While effective for many, their injectable nature and higher cost can be barriers to consistent use for some patients.

Mysimba's oral formulation and potentially lower price point present an advantage in terms of accessibility and patient adherence. The drug was previously available in Europe but was withdrawn from the market. However, its re-evaluation by health experts highlights the ongoing search for diverse and effective weight-management strategies beyond the currently trending injectables.